Please login to the form below

Advanced Accelerator Applications

This page shows the latest Advanced Accelerator Applications news and features for those working in and with pharma, biotech and healthcare.

Novartis chooses internal replacement for US pharma president role

She joined the company from Advanced Accelerator Applications after it was acquired by Novartis and has also served as the head of pharmaceuticals for Europe at the company.

Latest news

Novartis buys cancer specialist Endocyte for $2.1bn

177. Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours, acquired along with French company Advanced Accelerator Applications for $3.9bn a year ago.
Novartis follows Pfizer and freezes US prices this year

ploughing the cash back into the pipeline-enriching acquisitions of gene therapy company AveXis and radiopharma specialist Advanced Accelerator Applications – and going ahead with the spin-off its Alcon eyecare unit.
AAA board presses go on $3.9bn Novartis takeover

French radiopharmaceuticals firm backs the cash offer. Novartis has started its cash tender offer for French firm Advanced Accelerator Applications, which specialises in radiopharmaceuticals to treat cancer.
Novartis to buy French radiopharma specialist AAA for $3.9bn

Novartis has agreed a $3.9bn deal to buy Advanced Accelerator Applications, a French company specialising in nuclear medicines used to treat tumours. ... The transaction gives Novartis “both near-term product launches as well as a new technology
AAA’s orphan drug Lutathera wins EU green light

The first-in-class drug treats adults with GEP-NET. Advanced Accelerator Applications’ (AAA) Lutathera (lutetium oxodotreotide) has received European approval to treat adults with unresectable or metastatic, somatostatin receptor positive

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest appointments

Abeona Therapeutics appoints new additions to board of directors

Buono was previously the chief executive officer and president of Advanced Accelerator Applications, an international radiopharmaceutical company he founded in 2002.
Former Roche development head joins Asana advisory board

The founder of KAPital Consulting, Dr Dhingra currently serves on the boards of Exosome Diagnostics as chairman of the board, Advanced Accelerator Applications, Five Prime and Autolus.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

3 Monkeys Zeno

If you’d like to know more healthcare@3monkeyszeno.com Or visit; Merck, Bayer, Boehringher Ingelheim, Novartis, Hologic, Netflix, SilverCloud, Advanced Accelerator Applications, Perrigo.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Account Director: Competitive

Healthcare Lead Copywriter: Competitive

Healthcare Senior Account Manager: Competitive

Medical Editor: Competitive

PMHub

Add my company

Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised: In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised: In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding: When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...